| |
HR
|
95%CI
|
P
|
|---|
|
Stage I
| | | |
|
Chemotherapy regimens
| | | |
|
5-FU
|
1
| | |
|
No-chemo
|
1.021
|
0.459-2.273
|
0.960
|
|
Oxaliplatin
|
1.002
|
0.215-4.670
|
0.998
|
|
Stage II
| | | |
|
ypT category
| | | |
|
ypT3
|
1
| | |
|
ypT4a
|
1.187
|
0.291-4.841
|
0.811
|
|
ypT4b
|
1.878
|
1.058-3.334
|
0.031
|
|
Postoperative radiotherapy
| | | |
|
No
|
1
| | |
|
Yes
|
1.870
|
1.159-3.018
|
0.010
|
|
Histologic type
| | | |
|
Adenocarcinoma
|
1
| | |
|
Mucinous carcinoma
|
1.877
|
1.138-3.094
|
0.014
|
|
Signet-ring cell carcinoma
|
8.078
|
2.351-27.748
|
0.001
|
|
Chemotherapy regimens
| | | |
|
5-FU
|
1
| | |
|
No-chemo
|
1.393
|
0.903-2.148
|
0.134
|
|
Oxaliplatin
|
0.926
|
0.438-1.956
|
0.840
|
|
Stage III
| | | |
|
ypT category
| | | |
|
ypT1
|
1.150
|
0.491-2.692
|
0.747
|
|
ypT2
|
0.759
|
0.436-1.321
|
0.329
|
|
ypT3
|
1
| | |
|
ypT4a
|
0.691
|
0.244-1.959
|
0.487
|
|
ypT4b
|
1.592
|
0.934-2.713
|
0.088
|
|
ypN category
| | | |
|
ypN1a
|
1
| | |
|
ypN1b
|
1.233
|
0.825-1.844
|
0.306
|
|
ypN2a
|
1.468
|
0.905-2.381
|
0.119
|
|
ypN2b
|
2.098
|
1.310-3.357
|
0.002
|
|
Residence location
| | | |
|
Big Metro
|
1
| | |
|
Metro or Urban
|
1.147
|
0.822-1.600
|
0.419
|
|
Less Urban or Rural
|
0.487
|
0.257-0.923
|
0.027
|
|
Histologic type
| | | |
|
Adenocarcinoma
|
1
| | |
|
Mucinous carcinoma
|
1.466
|
0.993-2.163
|
0.054
|
|
Signet-ring cell carcinoma
|
1.220
|
0.459-3.239
|
0.690
|
|
Histologic grade
| | | |
|
Well
|
0.716
|
0.229-2.239
|
0.565
|
|
Moderate
|
1
| | |
|
Poor
|
1.650
|
0.753-3.619
|
0.211
|
|
Undifferentiated
|
2.817
|
0.891-8.910
|
0.078
|
|
Unknown
|
1.037
|
0.496-2.171
|
0.922
|
|
Chemotherapy regimens
| | | |
|
5-FU
|
1
| | |
|
No-chemo
|
1.547
|
1.101-2.173
|
0.012
|
|
Oxaliplatin
|
0.626
|
0.372-1.054
|
0.078
|
-
Abbreviations: No-chemo without postoperative chemotherapy, 5-FU 5-fluorouracil, CI Confidential intervals.
